Boston Scientific (NYSE: BSX) CEO adds 186,240 shares in open-market buy
Rhea-AI Filing Summary
Boston Scientific CEO Michael F. Mahoney purchased 186,240 shares of common stock on August 3, 2026 at a weighted average price of $48.3323 per share, with individual trades between $47.87 and $48.47. After this open-market buy, he directly owns 1,590,024 shares and indirectly holds 22,119 shares via a 401(k) Retirement Savings Plan following a discretionary rebalancing transaction at $48.4300 per share.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 208,359 shares
Net Buy
2 txns
Insider
Mahoney Michael F
Role
Chairman, President & CEO
Bought
186,240 shs ($9.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1 | 186,240 | $48.3323 | $9.00M |
| Discretionary | Common Stock F2 | 22,119 | $48.43 | $1.07M |
Holdings After Transaction:
Common Stock — 1,590,024 shares (Direct);
Common Stock — 22,119 shares (Indirect, By 401(k))
Footnotes (2)
- F1. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.87 to $48.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F2. Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
Key Figures
Shares purchased (direct): 186240.0000 shares
Weighted average purchase price: $48.3323 per share
Direct holdings after transaction: 1590024.0000 shares
+3 more
6 metrics
Shares purchased (direct)
186240.0000 shares
Common Stock purchased on 2026-08-03 in open-market transaction
Weighted average purchase price
$48.3323 per share
Open-market Common Stock buy with trades from $47.87 to $48.47
Direct holdings after transaction
1590024.0000 shares
Directly owned Common Stock following 2026-08-03 purchase
Shares acquired via 401(k)
22119.0000 shares
Discretionary rebalancing under 401(k) Retirement Savings Plan
401(k) transaction price
$48.4300 per share
Price for shares acquired indirectly by 401(k) on 2026-08-03
Net buy shares reported
186240 shares
Net buy direction from transaction summary (non-derivative)
Key Terms
weighted average purchase price, discretionary transaction, Rule 16b-3(f), 401(k) Retirement Savings Plan
4 terms
weighted average purchase price financial
"Represents the weighted average purchase price."
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
discretionary transaction regulatory
"resulted in a discretionary transaction in shares of the Company's common stock."
Rule 16b-3(f) regulatory
"Discretionary transaction under Rule 16b-3(f)"
401(k) Retirement Savings Plan financial
"under the Company's 401(k) Retirement Savings Plan"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider purchase did Boston Scientific (BSX) CEO Michael Mahoney report?
Michael Mahoney reported buying 186,240 shares of Boston Scientific common stock on August 3, 2026. The open-market transaction used a $48.3323 weighted average price, with individual trades executed between $47.87 and $48.47 per share.
Were the Boston Scientific (BSX) insider transactions made under a Rule 10b5-1 plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked as an affirmative plan. The filing instead describes an open-market purchase and a discretionary 401(k) rebalancing transaction, without identifying them as executed under a 10b5-1 trading plan.